A Phase 4 interventional study of Secukinumab and Placebo in Plaque Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-10.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.
Among the 54 studies testing secukinumab in Psoriasis, this one is the 31st largest by enrollment, is one of 5 that started in 2017, is one of 17 in phase 4, and was the 36th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
University of Athens · Sites in Greece
Ages 18–80 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Singapore General Hospital · Sites in Singapore
Ages 22–90
By country, each count listing its studies:
secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 24 · Phase 4 17
First in 2007; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 124 across the 54 interventional studies. Of the 46 that completed or were terminated, 38 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 54 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
68 studies in Psoriasis by Novartis: 3 open now, 4 under way, none of them phase 3. Of 61 finished, 41 (67%) have results posted.
Among the 68 studies in Psoriasis by Novartis, this one is the 35th largest by enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2017, is one of 6 in phase 4, and was the 46th registered.
Novartis’s Psoriasis studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing secukinumab in Psoriasis, from their registry updates:
Among Novartis’s 68 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study provided a comparison of secukinumab to placebo with respect to skin inflammation as measured by skin exams in comparison to skin biopsies, adipose tissue and blood sample analyses.
This was a randomized, double-blind, placebo-controlled, multicenter design. Patients with moderate to severe plaque psoriasis received secukinumab 300 mg or placebo, with randomization stratified by body weight (\< 90 kg, ≥ 90 kg). There were 5 periods to the study: Screening (1 to 4 weeks), Double-blind Treatment Period (12 weeks), Double-blind Induction Period (4 weeks), Open-label Treatment Period (36 weeks), and Follow-up Period (1 week).
During the Double-blind Treatment Period, all patients attended study visits at Baseline, Weeks 1, 2, 3, 4, 8, and 12, and all doses of study treatment were self-administered at the study site. Patients underwent lesional (LS) and non-lesional (NL) skin biopsies at Baseline and Week 12. Assessments for the primary efficacy variable were performed at Week 12 before patients received their Week 12 dose. During the Double-blind Induction Period, patients randomized to placebo were switched to secukinumab 300 mg for the remainder of the study.
K16 and skin histology/biomarkers were assessed from skin biopsies. The Psoriasis Assessment and Severity Index (PASI) and the Investigator's Global Assessment modified 2011 scale (IGA mod 2011) were performed at specified study visits. Safety was monitored by vital signs, weight, waist circumference, body mass index (BMI), and clinical laboratory tests (serum chemistry, hematology, highsensitivity C-reactive protein (hs-CRP), hemoglobin A1c (HbA1c), homeostatic assessment of insulin resistance (HOMA-IR), viral serology, serum and urine pregnancy).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Moderate to severe plaque psoriasis as defined at baseline by:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible patients received secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3 and 4 followed by monthly dosing up to Week 48
Biological: Secukinumab
Eligible patients received placebo at randomization, Weeks 1, 2, 3, 4, and 8. At Week 12, patients were switched to treatment with secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48
Biological: Placebo
Secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3, and 4 was followed by monthly dosing up to Week 48
Also known as: AIN457
Placebo s.c. at randomization, Weeks 1, 2, 3, 4, and 8; secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48
Number and Percentage of Participants With Response of Psoriasis Skin Lesions to Treatment at Week 12
Response in skin histology/K16 expression to treatment (answered no)
Time frame: 12 weeks
Number of and Percentage of Participants Who Achieved Psoriasis Area and Severity Index 90 (PASI 90) at Week 12
Psoriasis Area and Severity Index 90
Time frame: 12 weeks
Number and Percentage of Participants With Response of Psoriasis Skin Lesions to Treatment at Week 52
Response in skin histology/K16 expression to treatment (answered no)
Time frame: 52 weeks
Number of and Percentage of Participants Who Achieved Psoriasis Area and Severity Index 90 (PASI 90) at Week 52
Psoriasis Area and Severity Index 90
Time frame: 52 weeks
Change in Systolic Blood Pressure From Baseline to Week 12
Vital signs: summary statistics for change from baseline to Week 12
Time frame: baseline, Week 12
Change in Diastolic Blood Pressure From Baseline to Week 12
Vital signs: summary statistics for change from baseline to Week 12
Time frame: baseline, Week 12
Change in Body Weight From Baseline to Week 12
Vital signs: summary statistics for change from baseline to Week 12
Time frame: baseline, Week 12
Change in Glucose Level From Baseline to Week 12
Vital signs: summary statistics for change from baseline to Week 12
Time frame: baseline, Week 12
Change in Insulin Level From Baseline to Week 12
Vital signs: summary statistics for change from baseline to Week 12
Time frame: baseline, Week 12
Change in High-sensitivity C-reactive Protein (hsCRP) From Baseline to Week 12
Vital signs: summary statistics for change from baseline to Week 12
Time frame: baseline, Week 12
Change in Homeostatic Model Assessment of Insulin Resistance (UNIT) (HOMA-IR) From Baseline to Week 12
Vital signs: summary statistics for change from baseline to Week 12 Healthy Range: 1.0 (0.5-1.4) Less than 1.0 means you are insulin-sensitive which is optimal. Above 1.9 indicates early insulin resistance. Above 2.9 indicates significant insulin resistance.
Time frame: baseline, Week 12
Change in Hemoglobin A1c (HbA1c) Test for Diabetes Score From Baseline to Week 12
Vital signs: summary statistics for change from baseline to week 12 For people without diabetes, the normal range for the hemoglobin A1c level is between 4% and 5.6%. Hemoglobin A1c levels between 5.7% and 6.4% mean you have a higher chance of getting diabetes. Levels of 6.5% or higher mean you have diabetes.
Time frame: baseline, week 12
A total of 133 patients were screened for the study, with 82 (61.7%) of these completing the screening phase.
| Milestone | Secukinumab 300 mg | Placebo/Secukinumab 300 mg |
|---|---|---|
| Started | 54 | 28 |
| Completed | 44 | 27 |
| Not completed | 10 | 1 |
| Withdrew: Lost to follow-up | 6 | 0 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Non-compliance with study treatment | 1 | 0 |
Response in skin histology/K16 expression to treatment (answered no)
| Participants | Secukinumab 300 mg | Placebo |
|---|---|---|
| Number and Percentage of Participants With Response of Psoriasis Skin Lesions to Treatment at Week 12 | 43 | 1 |
Psoriasis Area and Severity Index 90
| Participants | Secukinumab 300 mg | Placebo |
|---|---|---|
| Number of and Percentage of Participants Who Achieved Psoriasis Area and Severity Index 90 (PASI 90) at Week 12 | 29 | 0 |
Response in skin histology/K16 expression to treatment (answered no)
| Participants | Secukinumab 300 mg | Placebo/Secukinumab 300 mg |
|---|---|---|
| Number and Percentage of Participants With Response of Psoriasis Skin Lesions to Treatment at Week 52 | 33 | 20 |
Psoriasis Area and Severity Index 90
| Participants | Secukinumab 300 mg | Placebo/Secukinumab 300 mg |
|---|---|---|
| Number of and Percentage of Participants Who Achieved Psoriasis Area and Severity Index 90 (PASI 90) at Week 52 | 31 | 20 |
Vital signs: summary statistics for change from baseline to Week 12
| mmHg | Secukinumab 300 mg | Placebo |
|---|---|---|
| Change in Systolic Blood Pressure From Baseline to Week 12 | -2.6 ± 11.05 | -1.5 ± 11.43 |
Vital signs: summary statistics for change from baseline to Week 12
| mmHg | Secukinumab 300 mg | Placebo |
|---|---|---|
| Change in Diastolic Blood Pressure From Baseline to Week 12 | -0.5 ± 7.92 | -0.2 ± 6.18 |
Vital signs: summary statistics for change from baseline to Week 12
| kg | Secukinumab 300 mg | Placebo |
|---|---|---|
| Change in Body Weight From Baseline to Week 12 | 0.340 ± 2.5475 | 0.096 ± 3.8729 |
Vital signs: summary statistics for change from baseline to Week 12
| mmol/L | Secukinumab 300 mg | Placebo |
|---|---|---|
| Change in Glucose Level From Baseline to Week 12 | 0.027 ± 0.7505 | 0.332 ± 1.2933 |
Vital signs: summary statistics for change from baseline to Week 12
| pmol/L | Secukinumab 300 mg | Placebo |
|---|---|---|
| Change in Insulin Level From Baseline to Week 12 | 15.037 ± 146.6361 | 141.035 ± 446.2800 |
Vital signs: summary statistics for change from baseline to Week 12
| mg/L | Secukinumab 300 mg | Placebo |
|---|---|---|
| Change in High-sensitivity C-reactive Protein (hsCRP) From Baseline to Week 12 | -5.010 ± 24.1279 | -1.273 ± 7.6405 |
Vital signs: summary statistics for change from baseline to Week 12 Healthy Range: 1.0 (0.5-1.4) Less than 1.0 means you are insulin-sensitive which is optimal. Above 1.9 indicates early insulin resistance. Above 2.9 indicates significant insulin resistance.
| SI units | Secukinumab 300 mg | Placebo |
|---|---|---|
| Change in Homeostatic Model Assessment of Insulin Resistance (UNIT) (HOMA-IR) From Baseline to Week 12 | 0.620 ± 6.0125 | 7.646 ± 26.5633 |
Vital signs: summary statistics for change from baseline to week 12 For people without diabetes, the normal range for the hemoglobin A1c level is between 4% and 5.6%. Hemoglobin A1c levels between 5.7% and 6.4% mean you have a higher chance of getting diabetes. Levels of 6.5% or higher mean you have diabetes.
| scores | Secukinumab 300 mg | Placebo |
|---|---|---|
| Change in Hemoglobin A1c (HbA1c) Test for Diabetes Score From Baseline to Week 12 | 0.018 ± 0.1889 | 0.014 ± 0.2138 |
Collected over Up to 52 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Secukinumab 300 mg | 0/54 (0%) | 1/54 (1.9%) | 39/54 (72.2%) |
| Placebo/Secukinumab 300 mg | 0/28 (0%) | 1/28 (3.6%) | 25/28 (89.3%) |
| Event | Secukinumab 300 mg | Placebo/Secukinumab 300 mg |
|---|---|---|
| Testis cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/54 | 1/28 |
| Suicidal ideationPsychiatric disorders | 1/54 | 0/28 |
| Event | Secukinumab 300 mg | Placebo/Secukinumab 300 mg |
|---|---|---|
| NasopharyngitisInfections and infestations | 10/54 | 1/28 |
| Upper respiratory tract infectionInfections and infestations | 7/54 | 1/28 |
| InfluenzaInfections and infestations | 2/54 | 3/28 |
| HypertensionVascular disorders | 0/54 | 3/28 |
| Back painMusculoskeletal and connective tissue disorders | 4/54 | 0/28 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/54 | 2/28 |
| BronchitisInfections and infestations | 0/54 | 2/28 |
| Urinary tract infectionInfections and infestations | 2/54 | 2/28 |
| Wound dehiscenceInjury, poisoning and procedural complications | 1/54 | 2/28 |
| HyperlipidaemiaMetabolism and nutrition disorders | 0/54 | 2/28 |
| Age, Continuous(years) | Secukinumab 300 mg | Placebo | Total |
|---|---|---|---|
| Mean | 41.5 ± 15.20 | 50.4 ± 13.10 | 44.5 ± 15.04 |
| Sex: Female, Male(Participants) | Secukinumab 300 mg | Placebo | Total |
|---|---|---|---|
| Female | 22 | 8 | 30 |
| Male | 32 | 20 | 52 |
| Race/Ethnicity, Customized(Participants) | Secukinumab 300 mg | Placebo | Total |
|---|---|---|---|
| Native American | 1 | 1 | 2 |
| Unknown | 1 | 0 | 1 |
| Caucasian | 44 | 19 | 63 |
| Black | 4 | 4 | 8 |
| Asian | 3 | 3 | 6 |
| Other | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Apr 2017 to primary completion in Apr 2018, 12 months.
Results were first posted in Mar 2020, 1 year 10 months after primary completion. A results delay was requested in Apr 2019.
Of 40 industry-sponsored phase 4 interventional studies under Psoriasis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 12 months is below that.
Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab